Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases

• Published in: Prostate cancer and prostatic diseases Vol. 26; no. 4; pp. 743 - 750
• Main Authors: Schoen, Martin W., Carson, Kenneth R., Eisen, Seth A., Bennett, Charles L., Luo, Suhong, Reimers, Melissa A., Knoche, Eric M., Whitmer, Alison L., Yan, Yan, Drake, Bettina F., Sanfilippo, Kristen M.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.12.2023; Nature Publishing Group
• Subjects: 692/308/409; 692/699/67/1059; Abiraterone Acetate - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cardiovascular disease; Cardiovascular Diseases; Clinical outcomes; Clinical trials; Comorbidity; Diabetes; Diabetes mellitus; Diabetes Mellitus - drug therapy; Drug interaction; Endocrine therapy; Hazard assessment; Health services; Humans; Male; Mens health; Metastases; Metastasis; Nitriles - therapeutic use; Observational studies; Prostate cancer; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - epidemiology; Prostatic Neoplasms, Castration-Resistant - pathology; Reproductive Medicine; Retrospective Studies; Sensitivity analysis; Survival; Survival analysis; Treatment Outcome; Veterans; United States > US
• ISSN: 1365-7852; 1476-5608
• DOI: 10.1038/s41391-022-00588-5

Background Comorbid diseases influence patient outcomes, yet little is known about how comorbidities interact with treatments for metastatic castrate-resistant prostate cancer (mCRPC). No head-to-head trials have compared the efficacy of abiraterone and enzalutamide - oral androgen-receptor targeted agents (ARTAs) for mCRPC. In patients with comorbid disease, outcomes with ARTAs may differ due to disparate mechanisms of action, adverse events, and drug interactions. Methods Retrospective observational study of US veterans initiating treatment for mCRPC with abiraterone or enzalutamide between September 2014 and June 2017. Treatment duration and overall survival (OS) was compared based on age and comorbid diseases. The association between ARTA and OS was assessed using Cox proportional hazards and propensity-score matched modeling while adjusting for potential confounders. Sensitivity analyses were performed based on patient age, comorbidities, and subsequent treatments for mCRPC. Results Of 5822 veterans treated for mCRPC, 43.0% initially received enzalutamide and 57.0% abiraterone. Veterans initially treated with enzalutamide versus abiraterone were older (mean 75.8 vs. 75.0 years) with higher mean Charlson comorbidity index (4.4 vs. 4.1), and higher rates of cardiovascular disease or diabetes (74.2% vs. 70.6%). In the entire population, veterans initially treated with enzalutamide had longer median OS compared to those initially treated with abiraterone (24.2 vs. 22.1 months, p  = 0.001). In veterans with cardiovascular disease or diabetes, median treatment duration with enzalutamide was longer (11.4 vs. 8.6 months, p  < 0.001) with longer median OS compared to abiraterone (23.2 vs. 20.5 months, p  < 0.001). In a propensity score matched cohort, enzalutamide was associated with decreased mortality compared to abiraterone (HR 0.90, 95% CI 0.84–0.96). Conclusions Veterans with cardiovascular disease or diabetes had longer treatment duration and OS with enzalutamide compared to abiraterone. Further study of ARTA selection may benefit men with metastatic castrate resistant prostate cancer and likely hormone sensitive prostate cancer, especially among patients with comorbid diseases.